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Fen/Phen and Valvular
Heart Disease: If It Sounds Too
Bad To Be True, Perhaps It Isn’t*
Nelson B. Schiller, MD
San Francisco, California
On the basis of a hypothesis that combination drug therapy
might be effective in promoting weight loss, Weintraub et
al. (1) administered two approved appetite suppressants
with different mechanisms of action in a double-blind trial
of 81 patients with simple obesity. They showed that the
combination, popularly known as fen/phen—fenfluramine
(a serotonergic agent) and phentermine (an amphetamine-
like central stimulant)—was just as effective in promoting
weight reduction as either agent alone but at lower individ-
ual doses and with fewer side effects and greater tolerance.
For the next decade, Weintraub and colleagues, with Na-
tional Institutes of Health funding, studied the efficacy of
this combination for periods as long as three years (2). In
these carefully conducted trials there was excellent patient
tolerance, minimal side effects and sustained weight reduc-
tion. No clinically manifest cardiac problems were recog-
nized.
In the four years after the publication of this research, this
off-label drug combination acquired a popular cachet and,
according to The Wall Street Journal (3), over 18 million
prescriptions for 6 million users were written in 1996.
Around that time I first learned of fen/phen and its
popularity when a long-time patient who had undergone
coronary artery bypass graft surgery five years earlier phoned
to ask if I would prescribe it so that he could “shed five
pounds” before an athletic event.
The same year, Connolly et al. (4) at the Mayo Clinic
began to take note of a series of obese women, mostly in
their 40s, with a history of taking this combination of diet
drugs, who presented with unusual valve lesions during
surgery. The first patient and four others underwent mitral
valve surgery and histologic study was done in the three
where the valve could not be repaired and was replaced.
Grossly, these valves were “glistening white, thickened and
tethered,” and histologically, the valve architecture was
intact with a superficial thick encasement of plaque; simi-
larities with the pathology of carcinoid and ergot-alkaloid–
induced valve diseases were noted. One patient also had
aortic and tricuspid surgery in addition to mitral valve
replacement. In describing their patient selection method-
ology, the authors wrote that eventually 24 patients were
found because “the serendipitous connection between these
individual cases was identified as a result of communication
among several physicians. . . .” Remarkably, many of these
patients came from a single clinic in neighboring Fargo,
North Dakota. The echocardiographic description of these
24 patients suggested a distinct and advanced condition. In
their words,
The mitral and aortic valves exhibited features similar to
diastolic doming of the anterior mitral leaflet, with pre-
served mobility and thickening and immobility of the
posterior leaflet were typical findings. Subvalvular involve-
ment was characterized by thickening and shortening of the
chordae tendineae. . . . The combination of abnormalities
resulted in malcoaptation and central regurgitation. The
aortic valve was characterized by thickening and mild
retraction. . . . With tricuspid involvement, the septal leaflet
was thickened and variably fixed to the septum. Color-flow
imaging demonstrated variable degrees of regurgitation in
all patients. Eight patients had Doppler echocardiographic
pulmonary hypertension (right ventricular systolic pressure
.50 mm Hg; range 52–93).
On the basis of prepublication knowledge of the Mayo
Clinic report, on July 8, 1997 the Food and Drug Admin-
istration (FDA) issued a Public Health Advisory citing 33
cases of “unusual valve morphology and regurgitation” (5)
associated with fen/phen usage. Simultaneously, the FDA
enlisted five sites with groups of patients taking fen/phen to
perform echocardiography on these patients. The results of
these unblinded collections were disquieting because by
August 29, 1997, 61 new cases, representing 32% of the
total examined, had been identified. On September 12,
1997, these results were presented to Wyeth Co. and posted
on the FDA Internet Website (6). In immediate response to
this information, fenfluramine and dexfenfluramine were
voluntarily withdrawn from the market.
Newspaper accounts of the manufacturer’s decision and
of the Mayo Clinic report were my first encounter with this
story. The description of a highly prevalent condition with
carcinoid-like characteristics particularly caught my atten-
tion. Taking the story at face value, it seemed that a genuine
public health crisis was brewing: in Dr. Connolly’s words, it
was the “largest drug-induced adverse reaction the FDA has
ever dealt with” (7). There were, however, a number of
aspects of the story that did not seem entirely plausible then
and continue to puzzle me. For example, our laboratory
published one of the larger series on the echocardiography
of carcinoid heart disease (8) that was based on over 15 years
of observations. How was it possible that a dramatic new
valve condition affecting over 30% of the large population of
exposed individuals and histologically identical to carcinoid
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had passed without our notice? How was it possible that our
laboratory, which had routinely measured Doppler pulmo-
nary pressure for over a decade (9) in an institution that
offers chronic prostacycline infusion for pulmonary hyper-
tension, would fail to have noticed a swell in cases of
pulmonary hypertension? How was it possible that an
outbreak of new significant mitral and aortic regurgitation
was not attended by any apparent increase in cases of
endocarditis among the previously healthy? How was it
possible that our tertiary referral center, with a reputation
for success in valve repair, had not seen a single case that
resembled those reported? How was it possible that the Bay
Area, whose inhabitants take a back seat to no one when it
comes to embracing trendy self-improvement medications
or substances, did not yield even more patients with these
findings than had been reported in the Mid West? How is
it possible that these regurgitant lesions seem to have
disappeared when they would be expected to worsen over
time?
For the next six months, there was a swell of patients who
had taken fen/phen now being studied in our echocardiog-
raphy laboratory. None had unusual valve lesions; two had
borderline pulmonary pressure Doppler readings that were
normal when catheterized. In the past six months these
referrals have ceased. During the last year, my conversations
with laboratory directors from major laboratories uncovered
only one who had encountered a patient who seemed to fit
the description of the Mayo Clinic cases. In addition, I
spoke with community cardiologists in several venues and
asked that they send me cases they thought might be related
to fen/phen. I received only two, and both showed low grade
mitral regurgitation without secondary anatomic or hemo-
dynamic consequences.
In the September 10, 1998 issue of the New England
Journal of Medicine, just over a year after publication of the
Connolly series (4), three studies and an editorial appeared
supporting the notion of valvulopathy related to fen/phen.
The first of these was the lead article by Khan et al. (10),
who performed echocardiography in 257 patients enrolled
in an open-label trial of fenfluaramine or dexfenflurmaine
either alone or in combination with phentremine. They
found that 22.7% of treated patients met the definition of
valvulopathy, whereas in an age-matched group of 239
obese subjects, recruited through advertisement, only 1.3%
were found to meet their definition of valve disease. The
echocardiograms were performed by several sonographers
on instruments from several vendors. No indication of the
methodology of examination was given in terms of trans-
ducer frequency, Nyquist settings or gain settings, and there
was no indication that the sonographers were blinded to the
histories of the patients. This consideration is important
because changes in gain and aliasing settings can alter the
intensity and size of the left atrial and left ventricular
outflow jets. Because a qualitative and highly subjective
evaluation of jet size was the only variable used in reaching
the conclusions of this study, the importance of this study
design feature merits emphasis. Furthermore, and even
more important, a single, unblinded observer read the
patient studies before a control group had been recruited.
Also, the study group included the original 60 patients that
the authors had reported to the FDA in July 1997. The
secondary readers were also potentially unblinded by the
study design as well because the dates the studies are
performed are automatically imprinted on tape-recorded
video images and all control subjects were collected at a later
date than study subjects. Also of importance is the use of the
FDA research definition of valve pathology to classify
patients. Although not printed in Khan’s paper, this defi-
nition is available on the FDA Internet site (6) and states
that the
. . . case definition for valvulopathy in the setting of appetite
suppressant use was aortic regurgitation of greater than
trace/trivial/minimal severity and/or mitral regurgitation of
greater than mild severity as documented by echocardiog-
raphy.
The source of this vague definition is obscure and depends
entirely on a qualitative, subjective impression of a highly
variable color flow signal. Although the methods section
lists such Doppler calculations as effective regurgitant mitral
orifice and pulmonary artery pressure, they do not appear in
the report. Although valve thickening is prominently men-
tioned in the Mayo Clinic report (4), it is not mentioned in
the Khan study.
In terms of reproducibility of readings there was consid-
erable disagreement between readers. For example, the
primary reader identified two patients with severe aortic
insufficiency, as did the secondary reader, but they were
different individuals. Although there were no individuals
identified as having severe mitral regurgitation, there was
66% disagreement in the moderate category in which the
primary reader found six examples.
The second study in the July 10, 1998 issue of the New
England Journal of Medicine, by Jick et al. (11), used a
computer data base kept by general practitioners in the
United Kingdom. Nearly 10,000 patients receiving appetite
suppressants were compared with a similar number of
control subjects. In the five years of observation, 11 patients
had a new murmur detected (8 of these confirmed by
echocardiography) compared with no patients in the control
group. No patient required an operation. In this study the
yearly risk of patients developing a new murmur of valve
regurgitation after taking fenfluramine or dexfenfluramine
appetite suppressants can be calculated to be ,0.07%, as
compared with 0.0% in control subjects. Although the
difference was statistically significant, this minuscule risk
contrasts sharply with the .20% risk in the Khan study.
The third study, in the July 10, 1998 issue of the New
England Journal of Medicine, was that of Weissman et al.
(12), who analyzed the echocardiograms of 1,072 obese
subjects, enrolled in a short-term, double-blind study of
dexfenfluramine. In contrast to the Khan study (10), they
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used a central reading center independent of the clinical
sites to analyze the echocardiograms. When the FDA
definition was used to identify valvulopathy, they found no
significant difference between the treatment and control
groups in terms of valvulopathy. However, according to the
Wall Street Journal (13), as a “precondition for publication,”
the editors of the New England Journal of Medicine insisted
that the authors emphasize a pooled analysis of trivial and
trace lesions. In this analysis, 17% of fenfluramine users had
detectable aortic regurgitation as opposed to 12% of placebo
recipients and 61% versus 54% for mitral regurgitation.
When pooled, these differences reached statistical signifi-
cance, but the apparent added risk was minimal.
In this issue of the Journal, Burger et al. (14) report the
results of echocardiograms in 226 subjects who took fen/
phen as part of a long-term (four-year) study. This study
See page 1153
differs from others because the duration of exposure to the
drugs was considerably longer (up to 30 months) and the
exposure to other potentially confounding drugs was also
analyzed. Two independent readers were employed, and
differences were decided in favor of the more severe lesion.
Only three subjects were found to have moderate aortic
regurgitation and only three to have moderate mitral regur-
gitation. Those with mild or moderate or severe regurgita-
tion did not differ in terms of duration of treatment,
treatment dosage or concomitant drug therapy. Finally,
when using the prevalence of valve disease in the Framing-
ham Study as a control, there were no apparent differences
in occurrence of either mitral or aortic regurgitation be-
tween drug users and the patient group.
It would seem, then, that as studies have become more
scientifically rigorous, the role of fen/phen in valve disease
appears to be approaching the vanishing point. Fenflura-
mine and dexfenfluramine are no longer prescribed and
valve lesions, whatever their historic reality, appear to have
vanished. The public should thus be greatly reassured.
Given these considerations, isn’t it time we move on to more
important matters? Unfortunately, there are at least three
pressing issues that preclude abandoning this topic. The first
of these is the financial impact of the fen/phen experience.
Committees representing national health organizations have
recommended that all individuals exposed undergo echocar-
diography. Conservatively, the price tag for 20 million
echocardiograms is over $4 billion. In addition, a legal
stampede has been unleashed. I have received many calls
from attorneys either seeking cases from among my patients
or asking me to provide expert testimony on both sides of
the issue. A $100 million settlement offer from Interneuron
Pharmaceutical, the company that developed dexfenflura-
mine is already before the courts (14), with more law suits
undoubtedly on the way. If the conclusion that fen/phen
and valve disease are cause and effect is not exhaustively
investigated and conclusively proved or disproved, this
substantial expenditure will continue to increase.
Second, an insidious problem raised by the fen/phen
experience is the almost universal misapplication of echo-
cardiography to the evaluation of valvular regurgitation.
Echocardiography with color flow mapping can detect the
most minute mitral and aortic regurgitant flow. Experienced
echocardiographers know that these small “leaks” are espe-
cially common in the mitral valve. As in any diagnostic
system, a high sensitivity for detection must lower the
specificity for disease severity. The specificity for severity is
further weakened by the degree to which an experienced
(and unblinded) sonographer can manipulate the appear-
ance of the regurgitant jet size and its apparent penetration
into the atrium by changing aliasing velocity (Nyquist),
transducer frequency, depth of image, gain or instrument
model. “Dial-a-jet” has been the facetious term applied to
this practice. However, the misunderstanding of the echo-
cardiography of regurgitation goes beyond the issue of
specificity. For example, the concepts of “mild mitral regur-
gitation” and “moderate mitral regurgitation,” as expressed
in the FDA definition, and their distinction from one
another, which form the basis for the concept of fen/phen
valvulopathy, have no defined medical or clinical meaning.
As befitting of “nonconcepts,” they are subjective, whimsical
and unmeasurable. For example, moderate mitral regurgi-
tation is one step below severe mitral regurgitation and, as
such, it should be defined in terms of its physiologic
consequences. If considered in this manner, it would be
reasonable to expect a hemodynamic burden of this magni-
tude to have some of the following sequellae: decreased
exercise capacity, grade 2-3/6 murmur, left ventricular
hypertrophy by electrocardiography, ventricular and atrial
dilation, an increase in ventricular mass, an elevation of
pulmonary pressure and a measured regurgitant fraction as
high as 50%. These variables can be clinically gauged,
measured by echocardiography and rationally used to ratio-
nally grade mitral regurgitation (15). Unfortunately, the
preferred approach in echocardiography laboratories in gen-
eral, and in fen/phen research in particular, has been to use
the confederacy of vague concepts embodied in the subjec-
tive and qualitative appearance of the color flow Doppler
signal.
Third, the valve disease described by Connolly et al. (4)
may have a geographic distribution that makes it more
prevalent—for example, in cooler climates. In an appropri-
ate environment, fen/phen may serve as a cofactor to
another, as yet unidentified, agent without which it is, itself,
harmless to valve tissue.
Although it is probably too late to rescue fen/phen from
oblivion and to stem the hemorrhaging of dollars, it is
desirable to take the incompetence out of mitral regurgita-
tion by rectifying the flaws in echocardiographic practice.
Encouraging laboratories to use quantitative Doppler meth-
ods (16) and to adopt a multifactorial index of severity (17)
are two suggested approaches. In this way the uncertainty
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that surrounds fen/phen will be less likely to recur in
another setting and our clinical approach to valve disease
will be strengthened. If the FDA is again confronted with a
condition that appears to rest primarily on echocardio-
graphic findings, it would be advisable that they recruit the
American Society of Echocardiography to consult on the
design of preliminary and secondary investigations. How-
ever, it is not premature to conclude that, on the basis of
evidence at hand, the association between fen/phen and
valvular heart disease is not too bad to be true (if true at all).
Disclosure
Dr. Schiller has consulted with counsel representing A. H.
Robbins, American Home Products and Wyeth-Ayerst and
may continue to do so. However, the opinions expressed
here are entirely his own.
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